EGFR and neoplasm: For example, CTX resistant patients show a baseline increased expression of gene signatures specific for monocytic infiltrates [47], while macrophage engagement by the serum of anti-EGFR cetuximab was shown to enhance the immunosuppressive, proangiogenic and protumoral functions of tumor-associated macrophages both in animals [48] and humans [49].